| Literature DB >> 31566901 |
Gaurav Nepal1, Rajeev Ojha2, Hari Prasad Dulal3, Binod Kumar Yadav4.
Abstract
BACKGROUND: Endothelin (ET)-1 is a potent vasoconstrictor peptide produced by endothelial cells and associated with vascular dysfunction and cardiovascular disease. Lys198Asn is a single-nucleotide polymorphism (SNP) of gene encoding ET-1 (EDN1). It is hypothesized that it might have a role in altering ET-1 and ultimately leading to vascular dysfunction and ischemic stroke. We therefore conducted a meta-analysis to investigate the association between Lys198Asn polymorphism of EDN1 gene and susceptibility of ischemic stroke.Entities:
Keywords: EDN1; K198N; Lys198Asn; cerebral infarction; endothelin-1; ischemic stroke; rs5370
Mesh:
Substances:
Year: 2019 PMID: 31566901 PMCID: PMC6790320 DOI: 10.1002/brb3.1424
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Figure 1Figure showing post‐translational modification of pre‐pro‐endothelin‐1 (PPET) protein encoded by endothelin‐1 gene (EDN1). Lys198Asn polymorphism does not fall within endothelin (ET)‐1 amino acids, but is located near the carboxy‐terminal region of PPET, which is removed from PPET by furin‐like enzyme during post‐translational processing steps
Figure 2Flow of systematic literature search and selection
Key methodological characteristics of included studies
| Study | Publication date | Country | Study design | Case/Control | Control matching criteria | HWE confirmation | Source of control | DNA source | Genotyping method | Methodological quality score |
|---|---|---|---|---|---|---|---|---|---|---|
| Gormley et al. | 2005 | UK | Case–control | 300/600 | Age, sex | Yes | CB | Venous blood | Allele‐specific PCR | 12 |
| Yamaguchi et al. | 2006 | Japan | Case–control | 264/1197 | Not matched | Yes | OB | Venous blood | PCR and oligonucleotide probes | 12 |
| Hang et al. | 2009 | China | Case–control | 46/50 | Age, sex | Yes | HB | Venous blood | PCR‐RFLP | 11 |
| Zhang et al. | 2014 | China | Case–control | 381/366 | Age, sex | Yes | HB | Venous blood | SNaPshot genotyping | 11 |
| Aslan et al. | 2017 | Turkey | Case–control | 100/100 | Not matched | Yes | HB | Venous blood | Real‐Time PCR | 11 |
| Dubovyk et al. | 2018 | Ukraine | Case–control | 200/200 | Not matched | Yes | HB | Venous blood | PCR‐RFLP | 12 |
Abbreviations: CB, Community based; HB, Hospital based; HWE, Hardy–Weinberg equilibrium; OB, Outpatient based; PCR‐RFLP, Polymerase chain reaction–restriction fragment length polymorphism.
Patient characteristics of studies included in this meta‐analysis
| Study | Ethnicity | Ischemic stroke type | Case | Control | ||||
|---|---|---|---|---|---|---|---|---|
| Mean ± | Mean ± | Male/Female | Mean ± | Mean ± | Male/Female | |||
| Gormley et al. | Caucasian | Small vessel disease | 67.10 ±10.26 | N/A | 198/102 | 66.85 ± 8.15 | N/A | 387/213 |
| Yamaguchi et al. | Asian | Large vessel disease | 68.6 ± 12.2 | 23.7 ± 3.5 | All female | 62.8 ± 12.0 | 23.5 ± 3.2 | All female |
| Hang et al. | Asian | Small vessel disease | 60.85 ± 13.28 |
Weight(kg): 66.48 ± 9.98 Height(cm): 158.35 ± 6.92 | 17/29 | 60.72 ± 11.70 |
Weight(kg): 63.32 ± 10.15 Height(cm): 159.60 ± 6.79 | 15/35 |
| Zhang et al. | Asian | Large vessel disease | 62.22 ± 10.81 | 24.27 ± 3.90 | 236/145 | 61.47 ± 9.64 | 24.34 ± 3.18 | 225/141 |
| Aslan et al. | Caucasian | Large vessel disease | 71.7 ± 10.6 | N/A | 54/66 | 65.8 ± 7.3 | N/A | 67/33 |
| Dubovyk et al. | Caucasian | Large vessel disease | 66.7 ± 10.1 | 27.9 ± 3.7 | 111/89 | 68.1 ± 13.9 | 27.3 ± 4.6 | 125/75 |
Abbreviations: BMI, Body mass index; N/A, Not available; SD, Standard deviation.
Figure 3Forest plot of the result for recessive model
Figure 4Forest plot of the result for dominant model
Figure 5Funnel plot for detection of publication bias in recessive model
Figure 6Funnel plot for detection of publication bias in dominant model
Subgroup analysis based on ethnicity and ischemic stroke subtype
| Subgroups | Recessive model | Dominant model |
|---|---|---|
| Caucasians | ||
| No of studies | 3 | 2 |
| Effect size | OR: 1.48; 95% CI: 0.74–2.97; | OR: 1.43; 95% CI: 1.03–1.98; |
| Heterogeneity |
|
|
| Asians | ||
| No of studies | 3 | 4 |
| Effect size | OR: 1.62; 95% CI: 0.92–2.86; | OR: 1.55; 95% CI: 0.97–2.46; |
| Heterogeneity |
|
|
| Large vessel disease | ||
| No of studies | 4 | 5 |
| Effect size | OR: 1.66; 95% CI: 0.98–2.8; | OR: 1.36; 95% CI: 1.06–1.75; |
| Heterogeneity |
|
|
| Small vessel disease | ||
| No of studies | 2 | 1 |
| Effect size | OR: 1.49; 95% CI: 0.58–3.83; | OR: 4.85; 95% CI: 1.76–13.32; |
| Heterogeneity |
|
|
Figure 7Meta‐regression plot for recessive model
Figure 8Meta‐regression plot for dominant model